Washington, DC, Sept. 26, 2017 -- This September 26 once again marks Mesothelioma Awareness Day. Mesothelioma is a cancer most people have seen in late-night commercials, but few know much about.
|
|||
The Mesothelioma Applied Research Foundation (Meso Foundation) is taking this opportunity to increase awareness of this cancer and educate the general public about its one main risk factor: asbestos.
Mesothelioma is a cancer usually associated with asbestos exposure. It is most often found in the lining of the lung or abdomen, and sometimes other organs as well.
The Meso Foundation states that it is a common misconception that asbestos has been banned or that regulations are in place to protect the public. In fact, they state, asbestos has still not been banned in the United States and while it is no longer manufactured here, it is still imported in a number of products. Although asbestos is regulated through workplace laws which help prevent occupational exposure, they do not protect the general public, as homes built between the 1940s and 1980s are likely to contain asbestos already (attic insulation, plaster, tiling, pipe insulation, etc…).
According to the organization, Do-It-Yourself-ers and “weekend renovators” are especially at risk when renovating or repairing homes and if doing the work in an occupied residence, all residents living in the home are at risk of inhaling microscopic asbestos fibers which are easily distributed throughout the home through HVAC system.
Mesothelioma can take between 20-50 years to develop from the time of inhalation of asbestos. The cancer is known as very aggressive and survival at five years from diagnosis is less than 10%.
However, for some patients appropriate treatment can greatly extend survival. Although the FDA approved only one treatment regimen for mesothelioma in 2004 (chemotherapy combination of Alimta/cisplatin), mesothelioma patients should be aware of all of their options many of which include surgery and experimental drugs (through clinical trials).
The Mesothelioma Applied Research Foundation can be a resource to those who have been diagnosed by helping them and their families navigate available treatment options, access treatment and clinical trials, and provide financial assistance. Mesothelioma patients who need help can contact Gleneara Bates, MSW, the organization’s Director of Research and Medical Outreach at (703) 879-3821 or [email protected].
Additional information can be found at www.curemeso.org.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/804ba210-e3e2-448d-8b1e-c400b1a4c3a4
Maja Belamaric Mesothelioma Applied Research Foundation 7038793822 [email protected]


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



